Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psoralen-inactivated SARS-CoV-2 vaccine
- Development stage
- Unknown
- Lead developer
- Naval Medical Research Command
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
psoralen-inactivated SARS-CoV-2 vaccine (SARS-CoV-2 PsIV) is an inactivated whole-virus vaccine candidate developed by the Naval Medical Research Command (NMRC) in collaboration with Vaxine and Wake Forest University. Unlike mRNA or subunit vaccines that target only the spike protein, SARS-CoV-2 PsIV is prepared by treating the whole SARS-CoV-2 virus (specifically the nCoV/USA-WA1/2020 strain) with the psoralen derivative 4′-aminomethyl-4,5′,8-trimethylpsoralen (AMT) followed by ultraviolet-A (UV-A) irradiation. This photochemical inactivation method selectively targets viral nucleic acids while preserving the native conformation of surface antigens (including the spike, nucleocapsid, envelope, and membrane proteins). Formulated with adjuvants such as Advax-CpG, the vaccine is designed to elicit broad, multi-antigenic neutralizing antibody and T-cell responses, potentially offering robust protection against emerging SARS-CoV-2 variants of concern.
- Other names
- psoralen-inactivated COVID-19 vaccinepsoralen-inactivated SARS-CoV-2 vaccineSARS-CoV-2 whole virus inactivated vaccineSARS-CoV2 whole virus inactivated vaccineSARS-CoV 2 whole virus inactivated vaccinewhole-virus psoralen-inactivated vaccine
02
Targets
ZIKV E (Zika virus envelope protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on psoralen-inactivated SARS-CoV-2 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psoralen-inactivated SARS-CoV-2 vaccine.